Literature DB >> 10497151

Pharmacokinetic models for the saturable distribution of paclitaxel.

M O Karlsson1, V Molnar, A Freijs, P Nygren, J Bergh, R Larsson.   

Abstract

Paclitaxel pharmacokinetics are nonlinear with saturable metabolism and saturable distribution to the tissues. The saturable distribution has in previous pharmacokinetic modeling been described as a saturable transport process, whereas the present study was undertaken to investigate alternative explanations. Using a sparse sampling scheme (on average 3.3 samples per profile), 101 plasma concentration-time profiles in 22 female patients with metastatic cancer of the breast or ovary were monitored. It was found that the observed data could be equally well described by saturable tissue binding as well as by capacity-limited tissue transport. The data were better described by a model where equilibrium was achieved with drug in the central rather than in the peripheral compartment. Models where the binding was assumed to be an instantaneous or a noninstantaneous process were tried, but the data did not allow resolution between these two possibilities. The value at which the saturable transport was half-maximal was 0.55 microM. The K(d) values of the binding models were 0.06 to 0.12 microM. These are close to the values reported as a threshold for drug toxicity of paclitaxel, suggesting a possible connection between the binding sites involved in the pharmacokinetics and the mechanism responsible for the toxicity. For all models, a saturable elimination of paclitaxel was included using the Michaelis-Menten model. K(m) for the elimination ranged in the different models from 2.5 to 5.6 microM.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10497151

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  24 in total

1.  Development and validation of limited sampling strategies for prediction of the systemic exposure to the novel anticancer agent E7070 (N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide).

Authors:  Charlotte van Kesteren; R A A Mathôt; E Raymond; J P Armand; P Fumoleau; C Punt; M Ravic; J Wanders; J H Beijnen; J H M Schellens
Journal:  Br J Clin Pharmacol       Date:  2002-11       Impact factor: 4.335

Review 2.  Population pharmacokinetics and pharmacodynamics for treatment optimization in clinical oncology.

Authors:  Anthe S Zandvliet; Jan H M Schellens; Jos H Beijnen; Alwin D R Huitema
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

3.  Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study.

Authors:  Markus Joerger; Stefanie Kraff; Alwin D R Huitema; Gary Feiss; Berta Moritz; Jan H M Schellens; Jos H Beijnen; Ulrich Jaehde
Journal:  Clin Pharmacokinet       Date:  2012-09-01       Impact factor: 6.447

4.  Disposition of paclitaxel (Taxol) and its metabolites in patients with advanced breast cancer (ABC) when combined with trastuzumab (Hercpetin).

Authors:  A Furtlehner; J Schueller; I Jarisch; E Ostermann; M Czejka
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2005 Jul-Sep       Impact factor: 2.441

5.  Complex pattern of interleukin-11-induced inflammation revealed by mathematically modeling the dynamics of C-reactive protein.

Authors:  Yuri Kheifetz; Moran Elishmereni; Zvia Agur
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-09-18       Impact factor: 2.745

6.  Population pharmacokinetics of ifosfamide and its dechloroethylated and hydroxylated metabolites in children with malignant disease: a sparse sampling approach.

Authors:  T Kerbusch; J de Kraker; R A Mathĵt; J H Beijnen
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

7.  Physiologically-based modeling and interspecies prediction of paclitaxel pharmacokinetics.

Authors:  Xiaowei Zang; Leonid Kagan
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-04-18       Impact factor: 2.745

8.  Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL.

Authors:  Milly E de Jonge; Alwin Dr Huitema; Jan Hm Schellens; Sjoerd Rodenhuis; Jos H Beijnen
Journal:  Br J Clin Pharmacol       Date:  2005-03       Impact factor: 4.335

Review 9.  Pharmacological effects of formulation vehicles : implications for cancer chemotherapy.

Authors:  Albert J ten Tije; Jaap Verweij; Walter J Loos; Alex Sparreboom
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

10.  Modeling dose-response relationships of the effects of fesoterodine in patients with overactive bladder.

Authors:  Linda Cardozo; Vik Khullar; Ahmed El-Tahtawy; Zhonghong Guan; Bimal Malhotra; David Staskin
Journal:  BMC Urol       Date:  2010-08-19       Impact factor: 2.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.